Divergent Human Papillomavirus Type 16 Variants Are Serologically Cross-Reactive

It is not known whether DNA sequence variants of human papillomavirus type 16 (HPV-16) are distinct serotypes. To examine this question, the reactivities of women's sera from Zaire (n = 97) and Denmark (n = 123) were compared in IgG-specific ELISAs based on virus-like particles (VLPs) composed...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 172; no. 6; pp. 1584 - 1587
Main Authors Cheng, Grace, Icenogle, Joseph P., Kirnbauer, Reinhard, Hubbert, Nancy L., St. Louis, Michael E., Han, Chenglong, Svare, Edith I., Kriiger Kjaer, Susanne, Lowy, Douglas R., Schiller, John T.
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.12.1995
University of Chicago Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It is not known whether DNA sequence variants of human papillomavirus type 16 (HPV-16) are distinct serotypes. To examine this question, the reactivities of women's sera from Zaire (n = 97) and Denmark (n = 123) were compared in IgG-specific ELISAs based on virus-like particles (VLPs) composed of the L1 major capsid protein derived from an HPV-16 variant common in central Africa (Z-1194)or one common in northern Europe (114K). These L1s differ in seven amino acids. There was a strong correlation between reactivity in the two assays for both sets of sera (correlation coefficients, 0.73 and 0.85 for Zairian and Danish sera, respectively). In only 1 serum was there evidence for a specific reaction to one but not the other VLP variant. The results support the conclusion that the virions of strains Z-1194 and 114K are serologically cross-reactive.
Bibliography:istex:49EDB49CC7A30FEC987D1F82EA491A631CF2F8B7
Present affiliations: Massachusetts Institute of Technology, Cambridge (G.C.); Department of Dermatology, University of Vienna Medical School, Vienna, Austria (R.K.).
ark:/67375/HXZ-NJTP0Z5F-V
Reprints or correspondence: Dr. John T. Schiller, Laboratory of Cellular Oncology, NCI, NIH, Building 36, Room 1D32, Bethesda, MD 20892.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/172.6.1584